Perilesional treatment of metastatic melanoma with interferon-β

Clinical and Experimental Dermatology

Volumn 34, Issue 7, 2009, Pages 793-799

  Fujimura, T ^a   Okuyama, R ^a   Ohtani, T ^a   Ito, Y ^a   Haga, T ^a   Hashimoto, A ^a   Aiba, S ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL INFILTRATION; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; MALE; MELANOMA; MONOCYTE; PRIORITY JOURNAL; SKIN METASTASIS; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; CD4 LYMPHOCYTE COUNT; CELLS, CULTURED; DENDRITIC CELLS; DRUG EVALUATION; FEMALE; HLA-DR ANTIGENS; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON-BETA; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70349507952     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03207.x     Document Type: Article

References (19)

1. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma. analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999 17 : 2105 2116.
2. Petrella T, Quirt I, Verma S et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007 33 : 484 496. (Pubitemid 47333669)
3. Coates AS, Segelov E. Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol 1994 5 : 249 251.
4. Rosenberg SA, Rapp HJ. Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 1976 60 : 419 430.
5. Ridolfi L, Ridolfi R. Preliminary experience of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology 2002 49 : 335 339.
6. Balch CM, Soong SJ, Murad TM et al. A multifactorial analysis of melanoma: IV-prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983 1 : 126 134.
7. Paul E, Muller I, Renner H et al. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional β-interferon injection. Melanoma Res 2003 13 : 611 617.
8. Miyakoshi J, Dobler KD, Allalunis-Turner J et al. Absence of IFNA and IFNB gene from human malignant glioma cell lines and lack of correlation with cellular sensitivity to interferon. Cancer Res 1990 50 : 278 283.
9. James CD, He J, Carlbom E et al. Chromosome 9 deletion mapping reveals interferon β and interferon β-1 gene deletion in human glial tumors. Cancer Res 1991 51 : 1684 1688.
10. Yoshida J, Mizuno M, Wakabayashi T. Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci 2004 95 : 858 865.
11. Kageshita T, Mizuno M, Ono T et al. Growth inhibition of human malignant melanoma transfected with the human interferon-β gene by means of cationic liposome. Melanoma Res 2001 11 : 337 342.
12. Creasey AA, Eppstein DA, Marsh YV et al. Growth regulation of melanoma cells by interferon and (2′-5′) oligoadenylate synthetase. Mol Cell Biol 1983 3 : 780 786.
13. Kaynor C, Xin M, Wakefield J et al. Direct evidence that IFN-β functions as a tumor-suppressor protein. J Interferon Cytokine Res 2002 22 : 1089 1098.
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guideline to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000 92 : 205 216. (Pubitemid 30099779)
15. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001 55 : 255 281.
16. Belardelli F, Gresser I. The neglected role of type I interferon in the T cell response: implication for its clinical use. Immunol Today 1996 17 : 369 372.
17. Rapprich H, Hagedorn M. Intralesional therapy of metastatic spreading melanoma with beta-interferon. J Dtsch Dermatol Ges 2006 4 : 743 746.
18. Redondo P, Del Olmo J, Lopez-Diaz de Cerio A et al. Imiquimod enhances the systemic attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol 2007 127 : 1673 1680.
19. Fujimura T, Nakagawa S, Ohtani T et al. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur J Immunol 2006 36 : 3371 3380.